Innate Biologics (USA) entered into a collaborative research agreement with The Wistar Institute, an international leader in biomedical research. Innate Biologics, a privately held company, is working with Wistar to develop a first-of-its-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways.
Innate Biologics, LLC is in the pre-clinical stage of developing novel cosmeceutical and therapeutic approaches for treating and preventing diseases and conditions whose root cause is profound inflammation. These approaches include transdermal applications to treat diverse inflammatory skin conditions that result from trauma, wound healing, reactive dermatitis, and age-related inflammation leading to collagen breakdown and thinning of the skin, including rhytides, commonly known as wrinkles.
The therapeutic platform is being developed to treat inflammation associated with auto-immune conditions such as asthma, rheumatoid arthritis, psoriasis, obesity, idiopathic pulmonary fibrosis, ulcerative colitis and Crohn’s disease, and other conditions and syndromes characterized by activation of inflammatory pathways. Innate Biologics, LLC is also developing a therapeutic platform to treat cancer, by attacking the inflammatory response in the local tumor microenvironment.
To accelerate development, Innate Biologics, LLC has secured a world class scientific advisory board with expertise in cosmeceuticals, therapeutics, therapeutic protein delivery and inflammatory pathway signal transduction mechanisms: Laura Niedernhofer (M.D., Ph.D., The Scripps Research Institute), Albert Baldwin (Ph.D., University of North Carolina School of Medicine, Lineberger Cancer Center), Paul Robbins (Ph.D., The Scripps Research Institute).
The Wistar Institute, an international leader in biomedical research with special expertise in cancer research and vaccine development, was founded in 1892 as the first independent nonprofit biomedical research institute in the United States.
Innate Biologics is targeting, treating and preventing inflammation and is developing a first of its kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways.